Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

If you don't know your blood type, you're not alone. However it is important medical information to know, and here's how you ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Professor Jae-Byum Chang and Professor Yeon Sik Jung's joint research team of the Department of Materials Science and ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an ...

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently ...

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...